CancerDrs

Lung Cancer clinical trials in Virginia

79 actively recruiting lung cancer trials at 26 sites across Virginia.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Virginia:
  • Oncology & Hematology Associates of Southwest Virginia,Inc.DBA Blue Ridge Cancer Care — Blacksburg, Virginia
  • Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer care| Emmett Medical & Surgical Center — Low Moor, Virginia
  • VCU Emergency Center at New Kent — Quinton, Virginia
  • VCU Medical Center Gateway Building — Richmond, Virginia
  • Virginia Commonwealth University — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Virginia:
  • UVA Comprehensive Cancer Center — Charlottesville, Virginia
  • UVA Health Fontaine Research Park — Charlottesville, Virginia
  • University of Virginia — Charlottesville, Virginia
  • UVA Health Cancer Care Pantops — Charlottesville, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Virginia:
  • Research Site — Fairfax, Virginia
  • Research Site — Fredericksburg, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in Virginia:
  • VCU Massey Cancer Center at Stony Point — Richmond, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Virginia:
  • Research Site — Fort Belvoir, Virginia
  • Research Site — Leesburg, Virginia
  • Research Site — Midlothian, Virginia
  • Research Site — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in Virginia:
  • Virginia Oncology Associates — Norfolk, Virginia
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has …

Sponsor: Pfizer
NCT ID: NCT07226999
Sites in Virginia:
  • Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Blacksburg, Virginia
  • Virginia Oncology Associates — Chesapeake, Virginia
  • Virginia Oncology Associates — Hampton, Virginia
  • Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Low Moor, Virginia
  • Virginia Oncology Associates — Newport News, Virginia
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Virginia:
  • Virginia Cancer Specialists - Arlington — Arlington, Virginia
  • Virginia Cancer Specialists — Fairfax, Virginia
  • VCU Massey Cancer Center — Richmond, Virginia
  • Shenandoah Oncology — Winchester, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Virginia:
  • Virginia Cancer Specialists ( Site 0167) — Fairfax, Virginia
  • Virginia Oncology Associates (VOA) ( Site 8101) — Norfolk, Virginia
  • VCU Health Adult Outpatient Pavillion ( Site 0193) — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in Virginia:
  • Local Institution - 0337 — Richmond, Virginia
  • Shenandoah Oncology, P.C. — Winchester, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …

Sponsor: AbbVie
NCT ID: NCT07365241
Sites in Virginia:
  • Blue Ridge Cancer Care - Blacksburg /ID# 281583 — Blacksburg, Virginia
  • Virginia Cancer Specialists - Fairfax /ID# 280710 — Fairfax, Virginia
  • Shenandoah Oncology /ID# 280699 — Winchester, Virginia
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Virginia:
  • University of Virginia Health System — Charlottesville, Virginia
  • Virginia Commonwealth University (Vcu) — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…

Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Virginia:
  • Virginia Cancer Specialists, PC — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…

Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in Virginia:
  • Virginia Cancer Specialists — Fairfax, Virginia
  • Virginia Commonwealth University — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The g…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07190248
Sites in Virginia:
  • Hematology Oncology Associates of Fredericksburg ( Site 9550) — Fredericksburg, Virginia
  • Blue Ridge Cancer Care ( Site 0144) — Roanoke, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…

Sponsor: InSightec
NCT ID: NCT05317858
Sites in Virginia:
  • Johnston Willis Hospital — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-…

Sponsor: SystImmune Inc.
NCT ID: NCT07625644
Sites in Virginia:
  • Virginia Cancer Specialists — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Virginia Cancer Institute — Richmond, Virginia
  • VCU Massey Cancer Center at Stony Point — Richmond, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
  • VCU Community Memorial Health Center — South Hill, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Virginia:
  • VCU Massey Cancer Center at Stony Point — Richmond, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
  • VCU Community Memorial Health Center — South Hill, Virginia
  • VCU Health Tappahannock Hospital — Tappahannock, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spr…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06287775
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread bey…

Sponsor: Pfizer
NCT ID: NCT07227298
Sites in Virginia:
  • VCU Medical Center Gateway Building — Richmond, Virginia
  • Virginia Commonwealth University — Richmond, Virginia
  • VCU Health Stony Point — Richmond, Virginia
  • Massey Cancer Center Clinical & Translational Research Lab — Richmond, Virginia
  • Virginia Commonwealth University — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Virginia:
  • Virginia Cancer Specialists — Fairfax, Virginia
View on ClinicalTrials.gov →

Showing 25 of 79 trials with sites in Virginia. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01